Investment Thesis
Outlook Therapeutics is a technically insolvent pre-revenue biotech company in critical financial distress: negative stockholders equity of -$38.5M, liabilities exceeding assets by $38.5M, severe liquidity crisis with 0.35x current ratio, and -$15.4M annual free cash burn against only $8.7M remaining cash, indicating potential insolvency within 6-12 months absent immediate capital infusion or revenue generation.
Strengths
- Maintains $8.7M in liquid cash providing near-term operational runway
- Long-term debt structure provides payment flexibility versus short-term obligations
- Pre-revenue biotech with potential clinical asset value if development programs advance
Risks
- Technical insolvency: negative stockholders equity of -$38.5M with cumulative losses exceeding all assets
- Acute liquidity crisis: 0.35x current ratio indicates severe inability to meet short-term liabilities from current assets
- Unsustainable cash burn: -$15.4M free cash flow annually against $8.7M cash reserves = critical funding need within 6-12 months
- Zero revenue with -$13.5M operating losses and no demonstrated path to profitability
- High leverage: $35.6M debt against $18.2M total assets and negative equity
Key Metrics to Watch
- Quarterly cash burn rate and cash runway remaining
- Clinical development milestones and regulatory progress
- Capital raise announcements, debt restructuring, or acquisition/merger activity
Financial Metrics
Revenue
0.0
Net Income
-23.1M
EPS (Diluted)
$-0.38
Free Cash Flow
-15.4M
Total Assets
18.2M
Cash
8.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-126.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.35x
Quick Ratio
0.28x
Debt/Equity
N/A
Debt/Assets
311.4%
Interest Coverage
-4.27x
Long-term Debt
35.6M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-13T21:12:28.979099 |
Data as of: 2025-12-31 |
Powered by Claude AI